NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF

NOVARTIS AG

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026

$150.20−0.42 (-0.28%)

Close on Oct 19, 2026

Market cap: $287.48B
P/E (TTM): 21.0
Dividend yield: –

NOVARTIS AG income statement

Annual QuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Cost of Revenue	13,699	12,827	12,472	11,582	11,735	15,121	14,425	14,510	13,633	17,520	17,404
Gross Profit	42,975	38,895	34,188	31,879	32,239	34,777	34,252	31,589	29,771	31,916	32,983
Research & Development	11,200	10,022	11,371	9,172	8,641	8,980	9,402	8,489	8,389	9,039	8,935
Selling, General & Admin	13,248	12,566	12,517	12,193	12,827	14,197	14,369	13,717	12,465	14,192	14,247
Selling & Marketing	–	–	–	–	–	–	–	–	12,861	11,998	11,772
General & Administrative	–	–	–	–	–	–	–	–	2,136	2,194	2,475
Operating Income	17,644	14,544	9,769	7,946	10,056	10,152	9,086	8,403	8,702	8,268	8,977
Interest Expense	1,144	1,006	855	800	787	869	850	932	750	707	655
Income from Equity Investments	-12	-38	-13	-11	15,337	673	659	6,438	1,108	703	266
Pretax Income	16,352	13,640	9,123	7,177	24,530	9,878	8,940	14,095	9,102	7,817	8,134
Income Tax Expense	2,385	1,701	551	1,128	1,625	1,807	1,793	1,295	1,603	1,119	1,106
Income from Continuing Operations	13,967	11,939	8,572	6,049	22,905	8,071	7,147	12,800	7,499	6,698	7,028
Income from Discontinued Operations	–	–	6,282	906	1,113	–	4,590	-186	204	–	10,766
Net Income incl. Noncontrolling Interests	13,967	11,939	14,854	6,955	24,018	8,071	11,737	12,614	7,703	6,698	17,794
Minority Interest in Earnings	-17	-2.00	4.00	0	-3.00	-1.00	5.00	3.00	0	-14	11
Net Income	13,984	11,941	14,850	6,955	24,021	8,072	11,732	12,611	7,703	6,712	17,783
EPS (Basic)(per share)	7.21	5.92	7.15	3.19	10.71	3.55	5.12	5.44	3.28	2.82	7.40
EPS (Diluted)(per share)	7.15	5.87	7.10	3.17	10.63	3.52	5.06	5.38	3.25	2.80	7.29
Shares Outstanding (Basic, Weighted)(shares)	1,939	2,018	2,077	2,181	2,243	2,277	2,291	2,319	2,346	2,378	2,403
Shares Outstanding (Diluted, Weighted)(shares)	1,955	2,035	2,092	2,197	2,260	2,296	2,319	2,344	2,371	2,400	2,438

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 31.0%

Financial strength

Current ratio: 0.86
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 24.0%

Valuation

P/E ratio: 21.0
Price to sales: –
Price to book: 6.92
Dividend yield: –